Bain Capital Life Sciences Investors as of June 30, 2023
Portfolio Holdings for Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors holds 32 positions in its portfolio as reported in the June 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Nuvalent Inc-a (NUVL) | 15.5 | $151M | 3.6M | 42.17 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 12.8 | $125M | 11M | 11.89 | |
| Springworks Therapeutics (SWTX) | 8.3 | $81M | 3.1M | 26.22 | |
| Pharvaris N V (PHVS) | 7.6 | $74M | 4.9M | 15.14 | |
| Disc Medicine (IRON) | 6.1 | $59M | 1.3M | 44.40 | |
| Crinetics Pharmaceuticals In (CRNX) | 4.3 | $42M | 2.3M | 18.02 | |
| Savara (SVRA) | 3.8 | $37M | 12M | 3.19 | |
| Aclaris Therapeutics (ACRS) | 3.6 | $35M | 3.4M | 10.37 | |
| Natera (NTRA) | 3.5 | $34M | 700k | 48.66 | |
| Dynavax Technologies Corp Com New (DVAX) | 3.2 | $31M | 2.4M | 12.92 | |
| X4 Pharmaceuticals (XFOR) | 3.2 | $31M | 16M | 1.94 | |
| Arcutis Biotherapeutics (ARQT) | 2.9 | $29M | 3.0M | 9.53 | |
| Mersana Therapeutics (MRSN) | 2.9 | $29M | 8.7M | 3.29 | |
| Cymabay Therapeutics | 2.8 | $27M | 2.5M | 10.95 | |
| Cabaletta Bio (CABA) | 2.7 | $26M | 2.0M | 12.91 | |
| Annexon (ANNX) | 2.1 | $20M | 5.7M | 3.52 | |
| Eqrx | 1.9 | $19M | 10M | 1.86 | |
| Nurix Therapeutics (NRIX) | 1.9 | $18M | 1.8M | 9.99 | |
| Solid Biosciences Com New (SLDB) | 1.7 | $16M | 3.1M | 5.24 | |
| Marinus Pharmaceuticals Com New (MRNS) | 1.6 | $16M | 1.4M | 10.86 | |
| 2seventy Bio Common Stock (TSVT) | 1.5 | $14M | 1.4M | 10.12 | |
| Atea Pharmaceuticals (AVIR) | 1.0 | $9.3M | 2.5M | 3.74 | |
| Rapid Micro Biosystems Class A Com (RPID) | 0.9 | $8.4M | 8.4M | 1.00 | |
| Nautilus Biotechnology (NAUT) | 0.8 | $7.7M | 2.0M | 3.87 | |
| Xilio Therapeutics (XLO) | 0.8 | $7.4M | 2.8M | 2.62 | |
| Syros Pharmaceuticals Com New (SYRS) | 0.7 | $6.7M | 2.1M | 3.15 | |
| Tango Therapeutics (TNGX) | 0.7 | $6.4M | 1.9M | 3.32 | |
| C4 Therapeutics Com Stk (CCCC) | 0.5 | $4.5M | 1.6M | 2.75 | |
| Third Harmonic Bio (THRD) | 0.3 | $3.1M | 641k | 4.81 | |
| Cara Therapeutics (CARA) | 0.3 | $2.6M | 935k | 2.83 | |
| Adagio Therapeutics (IVVD) | 0.2 | $2.0M | 1.9M | 1.05 | |
| Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) | 0.0 | $209k | 100k | 2.09 |
